Bellicum Pharmaceuticals (BLCM) has released an update to notify the public and investors about corporate charter and bylaws modifications.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
On January 24, 2024, the Company registered a Certificate of Designation for Series A Junior Preferred Stock, introducing a Super-Voting Share that provides its holder with voting power equivalent to the total common shares on record for shareholder meetings, contingent on proportional voting with common shares. These Super-Voting Shares are senior to common stock and other future junior stock but junior to existing preferred stock, are non-dividend bearing, and offer a nominal liquidation preference. Additionally, the Company amended its bylaws to change the quorum requirement for stockholder meetings to a majority of the voting power instead of a majority of outstanding shares.
For further insights into BLCM corporate activity, check out TipRanks’ Insiders Trading Activity page.
